Bruce Cree, MD, PhD, Professor of Clinical Neurology at the University of California San Francisco, discusses a post hoc analysis of patient pain and quality of life data in treatment with Uplizna (inebilizumab-cdon) for neuromyelitis optica.
Neuromyelitis optica spectrum disorders (NMOSD) affect the spinal cord and optic nerves. Symptoms include pain, weakness, bowel and bladder problems, and temporary vision loss. NMOSD usually occurs in adulthood, but symptoms may start at any age. A single attack of symptoms lasting months may occur, but in most people the symptoms come and go over time. People with NMOSD may develop permanent muscle weakness and vision loss. The cause of NMOSD is unknown. It occurs when the body’s immune system mistakenly attacks healthy cells in the spinal cord and eyes.
Inebilizumab targets B-cells that express CD19, cells that are the primary source of AQP4-IgG production. The N-MOmentum study was a phase 2/3 multicenter, double-blind, randomized, placebo-controlled trial testing the safety and efficacy of inebilizumab for the treatment of adults with NMO. A post hoc analysis of this study was presented at the 2024 European Academy of Neurology Congress, with a focus on patient-reported pain and quality of life outcomes in attack-free patients over three years.
It was observed that following three years on inebilizumab, quality life scores improved in 89% of patients with abnormal scores at baseline. Additionally, of the 39% of patients that had abnormal pain scores at baseline, 78% of patients reported improvements.
To learn more about NMOSD and other rare neurological disorders, visit https://checkrare.com/diseases/neurology-nervous-system-diseases/
